154 related articles for article (PubMed ID: 27784744)
21. Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.
Rossi D; Cortini F; Deambrogi C; Barbieri C; Cerri M; Franceschetti S; Conconi A; Capello D; Gaidano G
Leuk Res; 2007 Jan; 31(1):97-101. PubMed ID: 16620973
[TBL] [Abstract][Full Text] [Related]
22. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
23. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
24. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
[TBL] [Abstract][Full Text] [Related]
25. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
26. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.
Mullally A; Poveromo L; Schneider RK; Al-Shahrour F; Lane SW; Ebert BL
Blood; 2012 Jul; 120(1):166-72. PubMed ID: 22627765
[TBL] [Abstract][Full Text] [Related]
27. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
[TBL] [Abstract][Full Text] [Related]
28. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.
De Grandis M; Cambot M; Wautier MP; Cassinat B; Chomienne C; Colin Y; Wautier JL; Le Van Kim C; El Nemer W
Blood; 2013 Jan; 121(4):658-65. PubMed ID: 23160466
[TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
[TBL] [Abstract][Full Text] [Related]
30. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
31. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
32. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
33. [Correlation of JAK2V617F mutation burden with clinical features in patients with polycythemia vera and essential thrombocythemia].
Liu HX; Tong CR; Cai P; Teng W; Wang H; Zhang Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):742-5. PubMed ID: 19549399
[TBL] [Abstract][Full Text] [Related]
34. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
35. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
[TBL] [Abstract][Full Text] [Related]
36. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
Lengfelder E
Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
[TBL] [Abstract][Full Text] [Related]
37. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
[TBL] [Abstract][Full Text] [Related]
39. [Correlations of JAK2V617F point mutation with clinical and laboratory features in patients with polycythemia vera].
Shen YF; Xia J; Lu MZ; Jiang YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):121-4. PubMed ID: 19236761
[TBL] [Abstract][Full Text] [Related]
40. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]